Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
How long does it Take for Abasaglar® (insulin glargine) to Start Working?
The median onset of action for Abasaglar is approximately 1 to 2 hours.
UK_cFAQ_BIV048_ONSET
en-GB
Onset of Action
The onset of action for Abasalar
- varies with dose and among patient populations, and
- is expected to be shorter for patients with diabetes mellitus compared with healthy subjects.1
Additional Information in Healthy Subjects
3 single-site, randomized, double-blind, 2-treatment, 4-period, crossover, euglycemic clamp studies were conducted in healthy subjects to evaluate similarity in the pharmacokinetic and pharmacodynamic of
- Abasaglar
- the United States (US) - approved version of Lantus, and
- the European Union (EU) - approved version of Lantus.2
The median onset of action, defined as the time of first change of glucose infusion rate postdose, was similar between study groups and ranged from
- 0.81 to 2.10 hours for Abasaglar
- 1.70 to 1.87 hours for the US-approved version of Lantus, and
- 0.83 to 2.13 hours for the EU-approved version of Lantus.2
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Linnebjerg H, Lam ECQ, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226-2233. http://dx.doi.org/10.2337/dc14-2623
Date of Last Review: October 07, 2019
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays